http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019087957-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f664356294234e6c9aed711394a36e40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_395d42c6bb20d0c784e3247e5550596f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c9912fa01dade3ffa6f3efaae218f88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86f64b0c279aca409bb99ec9b1346671 |
| publicationDate | 2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019087957-A1 |
| titleOfInvention | Radioactive antitumor agent |
| abstract | This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that does not result in dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range. |
| priorityDate | 2017-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.